Frank J Beurskens Selected Research

Complement System Proteins (Complement)

1/2021	C1q binding to surface-bound IgG is stabilized by C1r2s2 proteases.
1/2020	DuoHexaBody-CD37®, a novel biparatopic CD37 antibody with enhanced Fc-mediated hexamerization as a potential therapy for B-cell malignancies.
1/2019	CD20 and CD37 antibodies synergize to activate complement by Fc-mediated clustering.
1/2017	Monoclonal Antibodies against Epidermal Growth Factor Receptor Acquire an Ability To Kill Tumor Cells through Complement Activation by Mutations That Selectively Facilitate the Hexamerization of IgG on Opsonized Cells.
1/2017	Hexamerization-enhanced CD20 antibody mediates complement-dependent cytotoxicity in serum genetically deficient in C9.
2/2016	Real-time analysis of the detailed sequence of cellular events in mAb-mediated complement-dependent cytotoxicity of B-cell lines and of chronic lymphocytic leukemia B-cells.
1/2016	A Novel Platform for the Potentiation of Therapeutic Antibodies Based on Antigen-Dependent Formation of IgG Hexamers at the Cell Surface.
1/2016	Antibodies That Efficiently Form Hexamers upon Antigen Binding Can Induce Complement-Dependent Cytotoxicity under Complement-Limiting Conditions.
11/2015	A Complement-Optimized EGFR Antibody Improves Cytotoxic Functions of Polymorphonuclear Cells against Tumor Cells.
11/2015	C1q, antibodies and anti-C1q autoantibodies.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Frank J Beurskens Research Topics

Disease

16	Neoplasms (Cancer) 01/2021 - 04/2010
10	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 01/2020 - 07/2009
4	Infections 01/2021 - 11/2015
2	Gonorrhea 01/2021 - 01/2019
1	Bacterial Infections (Bacterial Infection) 01/2021
1	Myasthenia Gravis 01/2017
1	Autoimmune Diseases (Autoimmune Disease) 01/2017
1	Non-Hodgkin Lymphoma (Lymphosarcoma) 01/2015
1	Vascular Diseases (Vascular Disease) 08/2011
1	Skin Diseases (Skin Disease) 07/2008
1	Inflammation (Inflammations) 07/2008

Drug/Important Bio-Agent (IBA)

14	Complement System Proteins (Complement)IBA 01/2021 - 12/2011
9	AntibodiesIBA 01/2020 - 04/2010
7	Monoclonal AntibodiesIBA 01/2021 - 12/2011
5	Immunoglobulin G (IgG)IBA 01/2021 - 07/2009
4	Rituximab (Mabthera)FDA Link 02/2016 - 09/2011
2	VaccinesIBA 01/2021 - 01/2019
2	ErbB Receptors (EGF Receptor)IBA 01/2017 - 04/2010
2	ofatumumab FDA Link 02/2016 - 12/2011
2	Complement Receptors (Complement Receptor)IBA 11/2015 - 12/2011
1	Immunoglobulins (Immunoglobulin)IBA 01/2021
1	DNA (Deoxyribonucleic Acid)IBA 01/2021
1	TNF-Related Apoptosis-Inducing Ligand ReceptorsIBA 10/2020
1	lacto-N-neotetraoseIBA 01/2020
1	EpitopesIBA 01/2020
1	galactosyl- beta(1- 3)- N- acetylglucosaminyl- beta(1- 3)galactoseIBA 01/2020
1	TetraspaninsIBA 01/2020
1	Cholinergic ReceptorsIBA 01/2017
1	AutoantibodiesIBA 01/2017
1	idelalisibIBA 01/2015
1	ibrutinibIBA 01/2015
1	Agammaglobulinaemia Tyrosine KinaseIBA 01/2015
1	AutoantigensIBA 03/2014
1	Proteins (Proteins, Gene)FDA Link 01/2014
1	Fc Receptors (Fc Receptor)IBA 04/2010
1	CytokinesIBA 07/2008
1	Interleukin-8 (Interleukin 8)IBA 07/2008

Therapy/Procedure

7	Therapeutics 01/2020 - 09/2011
5	Immunotherapy 01/2017 - 04/2010
1	Drug Therapy (Chemotherapy) 04/2012